naltrexone / Generic mfg. - LARVOL DELTA

SG01 Naltrexone: not a one-trick pony for opioid overdose. The use of naltrexone to successfully treat severe Hailey-Hailey disease. (PubMed, Br J Dermatol) - "In 2022, acitretin was commenced and uptitrated to 25 mg once daily...Other immunosuppressive agents such as methotrexate, ciclosporin and azathioprine have been described in the literature with varying efficacy...Naltrexone is postulated to work due to analgesic and anti-inflammatory effects. It is a well-tolerated treatment for severe HHD that has drastically improved both our patient's skin and his quality of life."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Dermatology • Genetic Disorders • Oncology • Pain • IL6 • TLR4

Differential Antipyretic Effects of Toll-Like Receptor 4 Signal Inhibitors in Male Rats. (PubMed, Fundam Clin Pharmacol) - "Data show that TLR4 signal inhibitors have differential antipyretic activity on fever suggesting that some alternative or complementary mechanisms might be operational for LPS-induced fever. Data also suggest that TLR4 signal inhibitors may be an alternative as a possible treatment option for DAMP-mediated clinical pathologies."

Journal • Preclinical • IL6 • TLR4

EXHITENTRE: EXHIT ENTRE Comparative Effectiveness Trial (clinicaltrials.gov) - P2/3 | N=344 | Completed | Sponsor: Gavin Bart | Active, not recruiting ➔ Completed | Trial primary completion date: Apr 2025 ➔ Aug 2025

HEOR • Trial completion • Trial primary completion date • Substance Abuse

Dual activation of 5-HT1A and μ-opioid receptors mediates dezocine's antidepressant effects in mice with comorbid pain and depression. (PubMed, Pharmacol Biochem Behav) - "This study demonstrates that dezocine alleviates pain-depression comorbidity by activating both 5-HT1A and μ-opioid receptor."

Journal • Preclinical • CNS Disorders • Depression • Neuralgia • Pain • Psychiatry

Intraoperative pain management for patients undergoing medication-assisted rehabilitation: a scoping review. (PubMed, BMC Anesthesiol) - No abstract available

Journal • Anesthesia • Pain • Substance Abuse

Reporting quality standards in gaming disorder treatment evidence: A systematic review. (PubMed, Acta Psychol (Amst)) - "There have been several improvements in GD treatment study design and reporting, including controls, randomization and follow up, reflecting an increasing number of higher quality trials for the condition. Most of the studies with higher reporting quality (i.e., scoring ≥30/46 on the CONSORT framework) were psychotherapy-based. Future research should employ designs with longer follow-ups, broader assessment of outcomes, and standardized ICD-11-aligned tools. Pharmacological treatments, including novel pharmacotherapies for other addictions (e.g., Naltrexone), are underexplored and lack high quality evidence."

Journal • CNS Disorders • Psychiatry

Real-world longitudinal treatment trajectories following opioid use disorder diagnosis among commercially-insured beneficiaries in the United States. (PubMed, J Subst Use Addict Treat) - "Findings highlight a significant discordance between real-world treatment patterns and evidence-based guidelines for OUD treatment."

Journal • Real-world evidence • Addiction (Opioid and Alcohol) • Substance Abuse

Pharmacological management of binge eating disorder. (PubMed, Ment Health Clin) - "Treatment guidelines for binge eating disorder (BED) lack substantial recommendations for specific pharmacological management beyond lisdexamfetamine. This may lead clinicians to question what other options are available for managing BED. The following clinical scenarios will review existing data examining the use of several pharmacological agents for BED, including stimulants, glucagon-like peptide-1 agonists, naltrexone, antidepressants, and antiseizure medications."

Journal • Binge Eating Disorder • CNS Disorders • Epilepsy

What's Hot, What's Not: Review of Pharmacological Options for Managing Burning Mouth Syndrome. (PubMed, Ann Pharmacother) - "Multiple agents with different mechanisms of action may be beneficial in the management of BMS. In the absence of treatment guidelines, providers may refer to this review when managing their patients."

Journal • Review • Pain

Quality of life and treatment effectiveness direct and indirect effects on cocaine abstinence outcomes during cocaine use disorder treatment. (PubMed, Drug Alcohol Depend) - "Overall QOL and environmental QOL are related to treatment response through their relationship with patients' perception of treatment effectiveness. TEA is directly related to cocaine abstinence at the end of treatment. QOL and TEA measures may serve as indicators of a need for additional support within care plans. These findings highlight the impact of a patient's sense of well-being and their perceived treatment effectiveness on biochemically validated cocaine abstinence."

HEOR • Journal • Addiction (Opioid and Alcohol)

RAISE: Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (clinicaltrials.gov) - P4 | N=120 | Active, not recruiting | Sponsor: Marta Peciña, MD PhD | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Naltrexone-An AUDacious Approach to Treating Acute Pancreatitis in Patients with AUD. (PubMed, Dig Dis Sci) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Pancreatitis

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse. (PubMed, bioRxiv) - "Specifically, we observed that two S1P receptor agonists FDA-approved for multiple sclerosis, fingolimod and ozanimod, and the more brain penetrant S1P 1 receptor agonist CYM5442, reduced binge alcohol drinking in the drinking in the dark (DID) paradigm in mice...Notably, CYM5442 was less aversive than naltrexone, an FDA-approved medication for the treatment of alcohol use disorder that shares a similar broad reducing action on alcohol intake and consummatory behavior...Lastly, gene expression analysis by RNA-Seq revealed that S1P regulates a complex set of genes in the transition to alcohol dependence. Overall, our results establish S1P signaling as a novel therapeutic target for alcohol use disorder."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Multiple Sclerosis

Combination Therapy for Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=45 | Not yet recruiting | Sponsor: Johns Hopkins University

New P2 trial • Addiction (Opioid and Alcohol)

Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial. (PubMed, Addiction) - "Primary care clinics that implement office-based addiction treatment by nurses increase patient-years of opioid use disorder (OUD) treatment in male but not female patients. Exploratory findings suggest that differences in the proportion of patients treated for OUD, rather than differences in the duration of OUD treatment, account for observed differences across groups."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse

Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries. (PubMed, Am J Drug Alcohol Abuse) - "During follow-up, 3.2% of enrollees experienced heroin/synthetic opioid overdose, with reduced risk more strongly associated with methadone (HR = 0.14, 95%CI = 0.12-0.15) and buprenorphine (HR = 0.23, 95%CI = 0.22-0.25) than naltrexone (HR = 0.70, 95%CI 0.64-0.77). Use of methadone and buprenorphine, and to a lesser extent naltrexone, are associated with lower overdose risk among Medicaid beneficiaries newly diagnosed with OUD. State and local policies aimed at increasing timely, equitable, and sustained treatment receipt are needed to address the opioid epidemic and reduce disparities."

Journal • Reimbursement • US reimbursement • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Willingness to receive medication for opioid use disorder (MOUD): A longitudinal analysis of social network support. (PubMed, Drug Alcohol Depend) - "Social network support for MOUD, both the initial level and change over time, was associated with participants' willingness to receive MOUD. These findings suggest that intervention development focused on increasing social network support may have utility in increasing uptake of MOUD."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (clinicaltrials.gov) - P=N/A | N=5 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial primary completion date: Nov 2025 ➔ Feb 2026

Trial primary completion date • Alopecia • Dermatology • Immunology

Alcohol RCT: Integrated Digital Intervention for Alcohol Use Disorder (clinicaltrials.gov) - P2/3 | N=242 | Completed | Sponsor: Quit Genius | Recruiting ➔ Completed | Phase classification: P3 ➔ P2/3 | Trial completion date: Oct 2024 ➔ Jul 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Phase classification • Trial completion • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol)

Managing Alcohol Use Disorder in Alcohol-Related Liver Disease. (PubMed, Clin Liver Dis) - "For long-term recovery, we also speak to the importance of non-pharmacological interventions, including mutual aid organizations such as alcohols anonymous, peer recovery specialists, and emerging digital tools. Through a combination of these different tools, we can aid in patients in alcohol consumption reduction, abstinence improvement and ALD complication management."

Journal • Review • Addiction (Opioid and Alcohol) • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis

Nanomolar TLR4 Antagonist CIAC101 Derived from (+)-Naltrexone Blocks Microglial Activation and Methamphetamine Addiction. (PubMed, J Med Chem) - "Mechanistically, CIAC101 reduced microglial activation and inflammatory gene expression within addiction-relevant circuits, notably medial prefrontal cortex and ventral tegmental area. Together, these data nominate CIAC101 as a potent, central nervous system (CNS)-penetrant TLR4 antagonist that couples robust antineuroinflammatory activity with efficacy against METH-evoked neurobehavioral adaptations, advancing a neuroimmune strategy for treating stimulant addiction."

IO biomarker • Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • TLR4

Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease. (PubMed, Curr Gastroenterol Rep) - "Naltrexone and acamprosate reduce the relapse in the general AUD population, though data in ALD are limited. Baclofen is the only drug tested in randomized trials in cirrhosis, with early benefit but mixed results in later studies. Gabapentin and topiramate are promising off-label options...Pharmacotherapy is effective yet underused for relapse prevention in ALD. Integration with behavioral interventions and multidisciplinary care is essential to expand access, evaluate novel therapies, and improve patient outcomes."

Journal • Review • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Transplantation • FGF21

Buprenorphine Treatment Duration and Adherence Among Youth and Subsequent Health Outcomes. (PubMed, Pediatrics) - "Medication adherence may prevent overdose, ED use, and hospitalization. Strategies to increase treatment duration/adherence likely avert harm."

HEOR • Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Prescription Sequence Symmetry Analysis for Detection of Chronic Opioid Use Adverse Event Signals Using Administrative Claims Data. (PubMed, Pharmacotherapy) - "PSSA applied to administrative claims data effectively identified both expected and potentially underrecognized adverse effects of long-term opioid use. This approach can enhance post-marketing surveillance by uncovering real-world prescribing cascades in older adults."

Adverse events • Journal • CNS Disorders • Pain

Evaluating the abuse potential of gabapentin in combination with buprenorphine using conditioned place preference in mice (Neuroscience 2025) - "These medications include methadone or suboxone (buprenorphine)...Mice were randomly assigned to one of 13 groups consisting of 8-14 mice, including; saline/saline, morphine/saline, GBP (100 or 300 mg/kg)/saline, BUP/saline, buprenorphine+GBP 100 or 300 mg/kg/saline, naltrexone/saline, naltrexone+GBP 100 or 300/saline, naltrexone/BUP and lastly, naltrexone+GBP 100 or 300+BUP/saline...The results of this research indicate that GBP may have significant abuse potential alone and when combined with buprenorphine. The results also indicate that the rewarding effects GBP may be mediated by activity on opiate receptors."

Combination therapy • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry